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The paper reviews the literature on vaccines against infectious coryza of 
chickens. Our knowledge of natural immunity, antigens involved in protection 
and the degree of cross-serovar protection provided by vaccines is summarized. 
The effect of variables such as antigen dose, inactivating agent and adjuvant 
type on vaccine efficacy is reviewed. The protective ability of a new generation 
infectious coryza vaccine based on a live attenuated strain of Haemophilus 
paragallinarum is discussed. 
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Introduction 
Infectious coryza, an upper respiratory tract infection of chickens caused by the 
bacterium Haemophilus paragallinarum, may occur in both growing chickens and 
layers. The major economic effect of the disease is an increased culling rate in 
meat chickens and a reduction in egg production (10-40%) in laying and breeding 
fowl, particularly on multi-age farms (Yamamoto, 1991). 
This paper reviews the literature on laboratory based evaluations of vaccines 
against infectious coryza. These studies have, in general, been performed using a 
challenge system based on either intrasinus or intranasal inoculation of H. 
paragallinarum. The paper does not attempt to provide a complete review of either 
the disease or the causative agent. Other reviews are available that cover these 
·areas (Blackall, 1989; Blackall and Yamamoto, 1990; Yamamoto, 1991). 
The organism 
The causative agent of infectious coryza, H. paragallinarum, is recognized as a 
Gram-negative organism that has an in vitro growth requirement for nicotinamide 
adenine dinucleotide (NAD; V factor). Recently, it has been recognized that some 
strains of H. paragallinarum isolated from poultry in South Africa are apparently 
V factor independent (Horner et al., 1992; Mouahid et al., 1992; Bragg et al., 1993). 
These strains have been shown to be typical H. paragallinarum in all other 
properties other than the fact that they do not require V factor in a complex 
medium (Horner et al., 1992; Mouahid et al., 1992). 
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The most widely used serotyping scheme for H. paragallinarum is that described 
by Page (1962) which recognizes three serovars (A, Band C). Some reports have 
cast doubt on the validity of Page's serovar B, suggesting that the members of this 
serovar are really only variants of serovars A or C (Sawata et al., 1980). However, 
it has recently been conclusively demonstrated that Page serovar B is a true 
serovar and that, with the exception of reference strain 0222, isolates of serovar B 
are fully pathogenic (Yamaguchi et al., 1990). 
The Kume serotyping scheme is an alternative to the Page scheme (Kume et al., 
1983). This recognizes three serogroups which have recently been shown to 
correspond to Page serovars A B and C (Blackall et al., 1990). Further minor 
differences exist and can be detected by the use of absorbed antisera, resulting in 
a typing scheme that, when initially proposed, recognized three serogroups and 
seven serovars. New serovars have recently been added to the Kume scheme and 
a new terminology has been adopted in which three serogroups (A B and C) are 
recognized, with the serovars within the serogroups being identified numerically. 
Currently the recognized Kume serovars are A-1, A-2, A-3, A-4, B-1, C-1, C-2, C-3 
and C-4 (Blackall et al., 1990). The new terminology emphasizes that the Page 
serovars and the Kume serogroups are equivalent. 
Natural immunity 
Chickens that recover from a natural infection of infectious coryza possess 
varying degrees of immunity. It has been shown that homologous immunity 
develops as early as two weeks after the initial exposure (Sato and Shifrine, 1964). 
Rimler et al. (1977) have shown that infection results in homologous immunity as 
well as some degree of heterologous immunity that extends across the Page 
serovars. 
Protective antigens 
The protective antigens of H. paragallinarum have not been convincingly 
identified. Sawata et al. (1979) suggested that the capsule of H. paragallinarum 
contains protective antigens. A crude polysaccharide has also been reported to 
provide protection that is limited to the Page serovar on which the vaccine is 
based (Iritani et al., 1981). 
Other studies have suggested that the haemagglutinin (HA) antigens may be 
protective antigens. Iritani et al. (1980) have shown that a purified haemagglutinin 
preparation from an agglutinin serovar A strain gave homologous protection. 
Several studies have noted a correlation between haemagglutination-inhibition 
(HI) titres and subsequent immunity to challenge. The most convincing evidence 
of the role of HA antigens in protection has only recently emerged. Takagi et al. 
(1991) have shown that chickens treated with monoclonal antibodies against the 
HA antigen of H. paragallinarum serovar A showed no clinical signs on challenge. 
The monoclonal antibodies also reduced the amount of the challenge organism 
present in the sinuses of the treated chickens compared with untreated controls 
(Takagi et al., 1991). 
There is considerable evidence that the protective antigens of H. paragallinarum 
are surface located. The antigens so far implicated have been the agglutinin 
antigens detected during Page serotyping, HA antigens and some component or 
components of the polysaccharide content of the cell. However, there still remains 
considerable confusion. It seems probable that there is not just one protective 
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antigen. A number of different antigens (outer membrane proteins, poly-
saccharides, lipopolysaccharides) are all likely to be involved. 
Cross-protection 
As mentioned above, there is evidence that natural infection results in subsequent 
immunity which offers both homologous and heterologous protection across the 
Page serovars (Sato and Shifrine, 1964; Rimler and Davis, 1977). In considering 
the literature on the degree of cross-serovar protection conferred by killed whole 
cell vaccines, there are two issues that can confuse the interpretation of research 
results. Firstly, different studies have defined 'protection' in differing ways. Some 
workers have evaluated protection only in terms of the presence or absence of 
clinical signs. Other workers have defined protection as meaning the absence of 
clinical signs, absence of mucus in the sinuses and absence of the challenge 
organism from the sinuses. Clearly, the last definition is far more demanding than 
the simple absence of clinical signs. 
The other issue that must be considered when examining cross-serovar 
protection relates to the serotyping scheme used. Most studies of cross-protection 
have involved isolates which have been serotyped by the Page scheme, i.e. into 
serovars A, B or C (Page, 1962). The recently developed Kume scheme (Kume et 
al., 1983) allows a finer serotyping of H. paragallinarum. Hence, it is possible for 
isolates of H. paragallinarum to belong to the same Page serovar but different 
Kume serovars. For example, isolates HP31 and HP60 are both Page serovar C (i.e. 
Kume serogroup C) but Kume serovars C-2 and C-4, respectively (Blackall et al., 
1990). 
Bearing the above constraints in mind, there is a general agreement in the 
literature about the cross-protection afforded by killed infectious coryza vaccines. 
Workers who have used vaccines based on egg yolk cultures or on tissue culture 
grown antigens have reported some degree of cross-protection between the Page 
serovars (Page et al., 1963; Wichmann and Wichmann, 1983). In contrast, killed 
vaccines based on broth grown antigen have been shown to provide little 
protection-across the Page serovars (Rimler et al., 1977; Kume et al., 1980b; Blackall 
and Reid, 1987). The explanation for the difference between egg-based and broth-
based vaccines in terms of their cross-protection appears to be related to their 
antigenic make-up. As natural infection results in cross-serovar protection, it 
seems likely the egg-produced antigen must resemble more closely the natural 
antigenic make-up of the organism in the chicken than does the broth grown 
antigen. The fact that egg-based vaccines provide some degree of cross-serovar 
protection should not be taken as a broad recommendation for this type of 
vaccine. Several studies have demonstrated that broth-based vaccines are more 
effective than egg-based vaccines in terms of homologous protection (Matsumoto 
and Yamamoto, 1975; Davis et al., 1976). 
Evaluating the literature about the relevance of cross-protection between the 
Kume serovars is more difficult as the Kume scheme has not yet been widely 
used. However, the overall evidence is that the Kume serogroups are not 
cross-protective. Within a Kume serogroup it appears that there is significant 
cross-protection between the serovars. Specific evidence to date is that, firstly, 
Kume serovars C-1 and C-2 and C-2 and C-4 are cross-protective; and, 
secondly, Kume serovars A-1 and C-1, A-1 and C-2, A-4 and C-2 and A-4 and 
C-4 are not cross-protective (Kume et al., 1980b; Blackall and Reid, 1987; 
Blackall, 1991 ). 
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Special mention needs to made of Page serovar B. Yamaguchi et al. (1991) have 
shown that different strains of serovar B provided only partial cross-protection 
amongst themselves. The confirmed existence of Page serovar B as a true serovar 
with full pathogenicity and its widespread existence - e.g. in Argentina and Brazil 
(Terzolo et al., 1993; Blackall et al., 1994b) - means that this serovar must be 
included in inactivated vaccines if the target poultry population is at risk from a 
serovar B challenge. The recognition of serovar B as a necessary component of 
infectious coryza vaccines is evidenced by the fact that commercial inactivated 
vaccines containing virulent serovar B strains are now available (Jacobs et al., 
1992). 
Growth media for vaccine production 
Different antigen preparation methods for infectious coryza vaccines have been 
reported including propagation in the yolk sac of chicken embryos, broth cultures 
and cell culture. Egg propagation was the method used in the early 1960s for the 
production of the earliest infectious coryza vaccines (Page et al., 1963). While these 
early vaccines did not give good protection against the clinical signs of infectious 
coryza, they did prevent the development of secondary air sac lesions and 
reduced the fall in egg production associated with outbreaks of infectious coryza. 
Subsequent work has shown that broth-based vaccines give better protection than 
egg-propagated products (Matsumoto and Yamamoto, 1975; Davis et al., 1976). 
There is one report of the production of infectious coryza vaccines in avian tissue 
cultures (Wichmann and Wichmann, 1983). This single study reported that this 
tissue culture-based vaccine was superior to vaccines produced in conventional 
broths (Wichmann and Wichmann, 1983). As most recent literature has involved 
the use of broths to produce infectious coryza vaccines, the remainder of this 
paper will be concerned with the efficacy of these broth-produced vaccines. 
A range of different broth media have been used for production of infectious 
coryza vaccines. Media that have been shown to result in effective vaccines 
include chicken meat infusions of various types (Matsumoto and Yamamoto, 
1971; Kume et al., 1980c) and a modified Casman broth (Rimler et al., 1975; 
Blackall and Reid, 1987). There appear to have been no direct comparisons of 
vaccines produced in different media so the relative efficacy of the media cannot 
be directly compared. 
Antigen levels 
The sole published study to date on the influence of antigen level established that 
108 colony forming ·Units per vaccine dose is the minimum needed to give good 
protection (Matsumoto and Yamamoto, 1975). 
Inactivating agents 
There is disagreement in the literature on the effect of different inactivating 
agents. Several studies have confirmed that thiomersal is effective (Matsumoto 
·and Yamamoto, 1975; Davis et al., 1976; Blackall and Reid, 1987). Others have 
reported that vaccines in which formalin was used as the inactivating agent were 
also effective (Rimler et al., 1975; Coetzee et al., 1982). 
There have been three direct comparisons of vaccines for which the antigen 
and adjuvant phases were exactly the same and only the inactivating agent 
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differed. In all three of these comparisons formalin reduced the efficacy of the 
vaccines although there was evidence that the effect was adjuvant specific. In 
one of these direct comparisons the use of formalin, compared with thiomersat 
resulted in a reduction in the efficacy of aluminium hydroxide-based vaccines 
(Blackall and Reid, 1987). The second study (Matsumoto and Yamamoto, 1971) 
found that formalin, compared with thiomersal, impaired the efficacy of a 
vaccine containing chrome alum as an adjuvant. However, these authors found 
no difference between thiomersal and formalin for vaccines containing alumin-
ium hydroxide gel. In the remaining study formalin reduced the efficacy of 
vaccines containing either mineral oil or aluminium hydroxide gel compared 
with the use of thiomersal (Davis et al., 1976). Overall, the evidence is that, 
while vaccines containing formalin as the inactivating agent can be protective, 
it is possible that a similar vaccine containing thiomersal would be even more 
efficient. 
Adjuvants 
The following sections review the literature on the different adjuvant systems that 
have been evaluated for inactivated infectious coryza vaccines. Again, it is 
important to realize that different criteria for protection have been used. Some of 
the conflicting results recorded in the literature may therefore arise from the use 
of different definitions of 'protection'. The various candidate vaccines will be 
reviewed from the view of both efficacy and safety (minimal adverse reactions to 
vaccination). 
The aspect of adverse reactions is an important consideration with infectious 
coryza vaccines. It has been suggested that adverse reactions are associated with 
either the adjuvant used or the lipopolysaccharide (LPS) present in the H. 
paragallinarum cells (Iritani et al., 1981). The LPS of H. paragallinarum has been 
shown to be lethal for embryonated chicken eggs and to be positive ir a pyrogen 
test (Konno and Nakase, 1977). Iritani et al. (1981) have also shown that a crudely 
purified polysaccharide extract contains a component that is toxic and causes 
hydropericardium following intravenous inoculation into chickens. Any records 
of adverse side reactions will be noted with the various adjuvant systems 
described below. 
Aluminium hydroxide gel 
A number of studies have confirmed that aluminium hydroxide gel is an 
effective adjuvant system (Matsumoto and Yamamoto, 1971; Davis et al., 1976; 
Kume et al., 1980c; Reid and Blackalt 1987). Chrome alum has also been found to 
be an effective adjuvant (Matsumoto and Yamamoto, 1971). Blackall and Reid 
(1987) found that the use of two commercial brands of aluminium hydroxide gel 
resulted in equally effective vaccines. All the studies that have evaluated 
aluminium hydroxide gel vaccines for adverse reactions have reported either no 
such reactions or only minor reactions at the vaccination site (Matsumoto and 
Yamamoto, 1971; Boycott et al., 1977; Blackall and Reid, 1987; Reid and Blackalt 
1987; Blackall et al., 1992). 
Mineral oil (single emulsion type) 
Those vaccines that contain mineral oil in a single emulsion system, i.e. a 
water-in-oil emulsion type, are described. The alternative system - a double 
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emulsion - is reviewed below. Clark and Godfrey (1961) found that egg-
propagated mineral oil-containing vaccines did confer some degree of protec-
tion compared with unvaccinated controls. The vaccinated chickens devel-
oped clinical signs although their severity was less than among the 
unvaccinated controls. In addition, the recovery of the vaccinated chickens 
was quicker and the incidence of complications was lower than for the 
unvaccinated controls (Clark and Godfrey, 1961). It is possible that the 
relatively low efficacy of this particular vaccine could have been due to 
factors other than the adjuvant system, e.g. the use of egg-propagated antigen 
or formalin as the inactivating agent. A later study by Matsumoto and 
Yamamoto (1971) of a commercial egg-propagated mineral oil-based vaccine 
showed similar low efficacy. 
In the case of broth propagation, there is still disagreement over the efficacy 
of mineral oil-based vaccines. In one study involving a direct comparison of 
vaccines based on the same antigen and different adjuvant systems, mineral 
oil-based vaccines conferred some protection, but much less than that given by 
a vaccine containing aluminium hydroxide gel as a vaccine (Reid and Blackalt 
1987). These authors evaluated two different concentrations of oil in the 
adjuvant component, but no improvement in the efficacy of the products 
resulted. In contrast, the direct comparison performed by Davis et al. (1976) 
resulted in no great difference between mineral oil- and aluminium hydroxide-
based vaccines. A study from South Africa has reported that mineral oil-based 
vaccines outperformed an aluminium hydroxide-containing vaccine (Coetzee et 
al., 1982). However, the results of this study must be treated with caution. The 
mineral oil-based vaccines contained a Page serovar A and B strain while the 
aluminium hydroxide gel vaccine contained a Page serovar A and C. As the 
challenge used was a mixture of Page serovar A and B, the aluminium 
hydroxide-based vaccine did not contain the appropriate serovars to match the 
challenge strains used. Jacobs et al. (1992) have re-cently reported that a vaccine 
that includes all three Page serovars and is based on a mineral oil emulsion 
gave good protection. 
The conflicting results over the efficacy of mineral oil-based vaccines are 
probably due to formulation issues. It would appear that, provided the adjuvant 
phase is formulated correctly;. it is possible to produce mineral oil-based infectious 
coryza vaccines that are efficacious. 
Another important aspect of mineral oil-based vaccines is the safety of the 
product. Mineral oil-based vaccines caused localized swellings in 15 of 20 
vaccinated birds and granulomas in 18 of 20 birds in one study (Reid and Blackalt 
1987). The authors considered the severity of these reactions to be unacceptable 
for commercial poultry operations. Other studies that have examined the use of 
mineral oil-based infectious coryza vaccines have not indicated whether any 
specific examinations for adverse reactions associated with vaccination were 
performed. This failure to record whether adverse reactions occurred or not is a 
major deficiency;. given the knowledge that H. paragallinarum LPS has been shown 
to be pyrogenic (Konno and Nakase, 1977). Candidate infectious coryza vaccines 
that contain mineral oil should be carefully screened for evidence of adverse side 
reactions. 
'rn an attempt to improve the efficacy of mineral oil-based vaccines, those that 
contain both aluminium hydroxide and mineral oil have been evaluated. While 
such vaccines were very effective, they gave even more severe adverse reactions 
than the mineral oil-based products (Reid and Blackalt 1987). 
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Mineral oil (double emulsion type) 
A double emulsion adjuvant represents an alternative method of combining the 
antigen phase and the adjuvant phase. It is created by re-emulsifying a simple 
water-in-oil emulsion in an outer water phase. In the initial evaluation (Blackall, 
1988) this type of vaccine was found to give a very poor level of protection. 
However, no evidence of adverse reactions to the vaccine was found. The oil used 
in the double emulsion type vaccines was the same batch as that used in simple 
water-in-oil vaccines which caused quite severe adverse reactions (Reid and 
Blackall, 1987). Yet, these adverse reactions were absent when the same oil was 
used in a double emulsion system. This suggests that the method of formulation 
of a double emulsion vaccine has some modulating effect upon the toxicity of 
mineral oil-based vaccines containing inactivated cells of H. paragallinarum. 
Recent work with double emulsion systems has given far more encouraging 
results. Double emulsion vaccines produced by an Australian manufacturer, 
experienced in the production of this type of vaccine, have been very effective and 
have given high levels of protection (Blackall et al., 1992). They have also caused 
very few adverse reactions at the site of inoculation (breast muscle). These results 
indicate that the double emulsion system, provided it is formulated correctly, 
represents both a safe and effective adjuvant system for infectious coryza 
vaccines. 
Alternative adjuvant systems 
There appear to have been only two studies of the suitability of adjuvants other 
than aluminium hydroxide and mineral oil for infectious coryza vaccines (Reid 
and Blackall, 1987; Blackall, 1988). Vaccines based on Quil A, a saponin, were 
found to have very little efficacy (Reid and Blackall, 1987). It is possible that a 
combined aluminium hydroxide gel-Quil A adjuvant may be more effective than 
either component alone. Such a combined adjuvant is worth evaluating. 
Similarly, the lipoidal amine, avridine, did not appear to have any effective 
adjuvant role in inactivated infectious coryza vaccines (Blackall, 1988). Avridine is 
a potent stimulator of interferon and is regarded as an effective adjuvant for the 
stimulation of mucosal immunity (Jensen, 1986). However, no efficacy could be 
found whether avridine was used as a sole adjuvant or in combination with both 
aluminium hydroxide gel and a double emulsion type adjuvant, or if used by the 
intramuscular or the intranasal routes (Blackall, 1988). As the three methods used 
to incorporate avridine into the vaccines have been shown by others to be 
effective, it appears unlikely that formulation problems are the explanation of the 
poor performance of avridine. It would appear that the adjuvant activity of 
avridine is not relevant for infectious coryza vaccines. 
Routes of administration 
The bulk of the literature on inactivated infectious coryza vaccines indicates that 
in most studies either the intramuscular or the subcutaneous route has been used 
(Matsumoto and Yamamoto, 1975; Davis et al., 1976). The only direct comparison 
of the effect of administering one vaccine by different routes established that an 
aluminium hydroxide-based vaccine was effective when given either subcuta-
neously (into the back of the neck) or intramuscularly (into breast muscle) but 
totally ineffective when given intranasally (Blackall and Reid, 1987). It has been 
reported that better protection is induced if aluminium hydroxide-based vaccine 
is given into the leg muscle rather than the breast muscle (Iritani et al., 1984). 
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Duration of immunity 
The duration of the immunity induced by infectious coryza vaccines has been 
examined in a number of studies. Matsumoto and Yamamoto (1975) were able to 
demonstrate that a single dose of aluminium hydroxide-based vaccine gave 
significant protection up to nine months after vaccination. Kume et al. (1980a) 
were able to achieve significant protection for up to 30 weeks after vaccination, 
although this work was performed using two doses of the aluminium hydroxide-
based vaccine. Blackall and Reid (1987) reported that aluminium hydroxide-based 
vaccines can give some degree of protection for up to 56 weeks after vaccination 
with a higher level of protection if two doses of the vaccine are given. 
The overall view from the literature is that, in vaccine evaluations based on 
short time periods, a single dose of an aluminium hydroxide-based vaccine is as 
effective as a double dose. However, it appears likely that, for longer term 
protection, aluminium hydroxide vaccines should be given as two doses, at least 
three weeks apart. 
Live infectious coryza vaccine 
The cross-serovar protection associated with natural infections (Rimler and Davis, 
1977) has been exploited by the use of 'controlled exposure' in which flocks are 
deliberately exposed to live H. paragallinarum before onset of lay (Yamamoto, 
1991). However, the use of live virulent H. paragallinarum strains is clearly a 
dangerous practice which should only be performed under limited and controlled 
conditions. A live, non-pathogenic strain of H. paragallinarum should have the 
advantage of cross-serovar protection without the disadvantage of adverse 
reactions associated with the use of a virulent pathogen. 
Blackall and colleagues have described their progress towards a live, 
attenuated infectious coryza vaccine. In the initial work they confirmed that. 
infection with a fully virulent serovar C strain provides subsequent protection 
against a different serovar C strain as well as a serovar A strain (Blackall et al., 
1993). Non-pathogenic mutated strains derived from a serovar A or a serovar C 
parent by chemical mutagenesis have been created (Blackall et al., 1993). A good 
level of protection against challenge from either a virulent serovar A or C strain 
following eyedrop vaccination with a non-pathogenic candidate vaccine strain 
has been demonstrated (Blackall et al., 1994a). 
Conclusions 
Research into effective infectious coryza vaccines has been in progress for over 30 
years. In that time much has been learnt about the requirements for an effective 
infectious coryza vaccine. It has been repeatedly demonstrated that whole cell 
vaccines that have been inactivated with thiomersal and contain aluminium 
hydroxide gel as the adjuvant provide good protection, particularly against 
clinical signs, but may not prevent infection. This protection is limited to the Page 
serovar(s) included 'in the vaccine. Alternative adjuvant systems such as mineral 
oil double emulsions have been shown to be equally effective provided that they 
are correctly formulated. Current work on a live infectious coryza vaccine may 
result in an entirely new approach to vaccination. 
While much has been gained over the past 30 years, definitive knowledge is 
still lacking in many areas. Recent development of monoclonal antibodies and the 
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application of these reagents, together with molecular biological techniques, 
promises a new era in infectious coryza vaccine research. It is possible that, in the 
near future, the key antigens responsible for protection may be identified. 
Similarly it may be possible to identify all those antigens associated with adverse 
reactions and so produce vaccines that give high levels of protection across all 
three Page serovars, but which avoid toxic or adverse side reactions. One of the 
challenges of the future will be to keep this potential 'super' vaccine cost effective 
and hence relevant to the practical world of poultry farming. 
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